Cargando…
Tumor-derived semaphorin 4A improves PD-1–blocking antibody efficacy by enhancing CD8(+) T cell cytotoxicity and proliferation
Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment, but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the immune system through multiple mechanisms in mice, although the role of human Sema4A in the tumor microenvironment remains unclea...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198637/ https://www.ncbi.nlm.nih.gov/pubmed/37205755 http://dx.doi.org/10.1126/sciadv.ade0718 |